{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:11:29Z","timestamp":1785510689922,"version":"3.56.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Genmab"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s12325-023-02775-9","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T03:02:58Z","timestamp":1706842978000},"page":"1226-1244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Treatment Outcomes with Standard of Care in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis"],"prefix":"10.1007","volume":"41","author":[{"given":"Andrew","family":"Ip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Mutebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupama","family":"Kalsekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Rivas","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Kamalakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Sacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,2]]},"reference":[{"key":"2775_CR1","unstructured":"Lymphoma - non-Hodgkin: Subtypes. 2022 28 Jun 2023]. https:\/\/www.cancer.net\/cancer-types\/lymphoma-non-hodgkin\/subtypes. Accessed 28 Jun 2023."},{"key":"2775_CR2","unstructured":"Cancer stat facts: NHL \u2014 diffuse large b-cell lymphoma (DLBCL). 2023 28 Jun 2023]. https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html. Accessed 28 Jun 2023."},{"key":"2775_CR3","doi-asserted-by":"publisher","first-page":"e1092","DOI":"10.1016\/j.clml.2022.08.008","volume":"22","author":"D Chihara","year":"2022","unstructured":"Chihara D, Johnston K, Bolatova T, et al. An epidemiological model to estimate the prevalence of diffuse large B-cell lymphoma in the United States. Clin Lymphoma Myeloma Leuk. 2022;22:e1092\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2775_CR4","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: B-cell lymphomas v5. 2023 [cited 2023 August 10, 2023]. https:\/\/www.nccn.org\/professionals\/physician_gls\/default_nojava.aspx. Accessed August 10, 2023."},{"key":"2775_CR5","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800\u20138.","journal-title":"Blood"},{"key":"2775_CR6","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857\u201361.","journal-title":"Blood"},{"key":"2775_CR7","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","volume":"117","author":"SM Aukema","year":"2011","unstructured":"Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood. 2011;117:2319\u201331.","journal-title":"Blood"},{"key":"2775_CR8","doi-asserted-by":"crossref","unstructured":"Hu S, Xu-Monette ZY, Tzankov A, et al. MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121:4021\u201331; quiz 250.","DOI":"10.1182\/blood-2012-10-460063"},{"key":"2775_CR9","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","volume":"124","author":"AM Petrich","year":"2014","unstructured":"Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124:2354\u201361.","journal-title":"Blood"},{"key":"2775_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1200\/JCO.2016.68.2740","volume":"35","author":"AF Herrera","year":"2017","unstructured":"Herrera AF, Mei M, Low L, et al. Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation. J Clin Oncol. 2017;35:24\u201331.","journal-title":"J Clin Oncol"},{"key":"2775_CR11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2217\/fon-2020-0522","volume":"17","author":"HC Chien","year":"2021","unstructured":"Chien HC, Morreall D, Patil V, et al. Real-world practice patterns and outcomes in veterans with relapsed\/refractory diffuse large B-cell lymphoma. Future Oncol. 2021;17:411\u201322.","journal-title":"Future Oncol"},{"issue":"suppl 1","key":"2775_CR12","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1182\/blood-2019-127719","volume":"134","author":"AS Halwani","year":"2019","unstructured":"Halwani AS, Chien H-C, Morreall DK, et al. Survival patterns in patients with relapsed or refractory diffuse large b cell lymphoma: treatment trajectories and responses after the first relapse [abstract]. Blood. 2019;134(suppl 1):1622.","journal-title":"Blood"},{"key":"2775_CR13","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00277-014-2271-1","volume":"94","author":"J Rovira","year":"2015","unstructured":"Rovira J, Valera A, Colomo L, et al. Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. Ann Hematol. 2015;94:803\u201312.","journal-title":"Ann Hematol"},{"key":"2775_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjh.14813","volume":"179","author":"U Farooq","year":"2017","unstructured":"Farooq U, Maurer MJ, Thompson CA, et al. Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. Br J Haematol. 2017;179:50\u201360.","journal-title":"Br J Haematol"},{"key":"2775_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.beha.2018.07.014","volume":"31","author":"C Sarkozy","year":"2018","unstructured":"Sarkozy C, Sehn LH. Management of relapsed\/refractory DLBCL. Best Pract Res Clin Haematol. 2018;31:209\u201316.","journal-title":"Best Pract Res Clin Haematol"},{"key":"2775_CR16","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","volume":"2011","author":"JW Friedberg","year":"2011","unstructured":"Friedberg JW. Relapsed\/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:498\u2013505.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2775_CR17","doi-asserted-by":"crossref","unstructured":"Yang X, Lalibert\u00e9 F, Germain G, et al. Real-world characteristics, treatment patterns, health care resource use, and costs of patients with diffuse large B-cell lymphoma in the U.S. oncologist. 2021;26:e817-e26.","DOI":"10.1002\/onco.13721"},{"key":"2775_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.clml.2021.11.011","volume":"22","author":"M Hamadani","year":"2022","unstructured":"Hamadani M, Liao L, Yang T, Chen L, Moskowitz C. Characteristics and clinical outcomes of patients with relapsed\/refractory diffuse large B-cell lymphoma who received at least 3 lines of therapies. Clin Lymphoma Myeloma Leuk. 2022;22:373\u201381.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2775_CR19","doi-asserted-by":"publisher","first-page":"204062071984158","DOI":"10.1177\/2040620719841581","volume":"10","author":"JC Chavez","year":"2019","unstructured":"Chavez JC, Bachmeier C, Kharfan-Dabaja MA. CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Ther Adv Hematol. 2019;10:2040620719841581.","journal-title":"Ther Adv Hematol"},{"key":"2775_CR20","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1182\/bloodadvances.2020002118","volume":"4","author":"D Sermer","year":"2020","unstructured":"Sermer D, Batlevi C, Palomba ML, et al. Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. Blood Adv. 2020;4:4669\u201378.","journal-title":"Blood Adv"},{"key":"2775_CR21","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","volume":"25","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN, Somerville RPT, Lu T, et al. Long-duration complete remissions of diffuse large b cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy. Mol Ther. 2017;25:2245\u201353.","journal-title":"Mol Ther"},{"key":"2775_CR22","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839\u201352.","journal-title":"Lancet"},{"key":"2775_CR23","unstructured":"Polivy [package insert]. South San Francisco, CA: Genentech, Inc.; 2020."},{"key":"2775_CR24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.19.00172","volume":"38","author":"LH Sehn","year":"2020","unstructured":"Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38:155\u201365.","journal-title":"J Clin Oncol"},{"key":"2775_CR25","unstructured":"Monjuvi [package insert]. Boston, MA, USA: MorphoSys US Inc.; 2021."},{"key":"2775_CR26","unstructured":"Zynlonta [package insert]. Murray Hill, NJ, USA: ADC Therapeutics SA; 2021."},{"key":"2775_CR27","unstructured":"Xpovio [package insert]. Newton, MA: Karyopharm Therapeutics Inc.; 2022."},{"key":"2775_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45\u201356.","journal-title":"N Engl J Med"},{"key":"2775_CR29","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"key":"2775_CR30","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1182\/blood.2022015789","volume":"139","author":"J Westin","year":"2022","unstructured":"Westin J, Sehn LH. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? Blood. 2022;139:2737\u201346.","journal-title":"Blood"},{"key":"2775_CR31","doi-asserted-by":"crossref","unstructured":"Di Rocco A, Di Rocco A, Farcomeni A, et al. Relapsed\/refractory diffuse large B-cell lymphoma (R\/R DLBCL) patients: a retrospective analysis of eligibility criteria for CAR-T cell therapy [abstract 2888]. Blood. 2019;134(Supplement_1):2888.","DOI":"10.1182\/blood-2019-131417"},{"key":"2775_CR32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.","journal-title":"Blood Cancer J"},{"key":"2775_CR33","first-page":"379","volume":"25","author":"J Thornton Snider","year":"2019","unstructured":"Thornton Snider J, Brauer M, Kee R, et al. The potential impact of CAR T-cell treatment delays on society. Am J Manag Care. 2019;25:379\u201386.","journal-title":"Am J Manag Care"},{"key":"2775_CR34","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/bjh.18209","volume":"198","author":"A Kuhnl","year":"2022","unstructured":"Kuhnl A, Roddie C, Kirkwood AA, et al. A national service for delivering CD19 CAR-Tin large B-cell lymphoma - the UK real-world experience. Br J Haematol. 2022;198:492\u2013502.","journal-title":"Br J Haematol"},{"issue":"suppl 3","key":"2775_CR35","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1097\/01.HS9.0000848704.84354.44","volume":"6","author":"AM Spanjaart","year":"2022","unstructured":"Spanjaart AM, Pennings E, Mutsaers P, et al. Population-based real world results of CD19-directed CAR T-cell therapy for patients with relapsed or refractory large B-CELL LYMPHOMA: a Dutch CAR T-cell tumorboard experience [abstract P1462]. HemaSphere. 2022;6(suppl 3):1344\u20135.","journal-title":"HemaSphere"},{"key":"2775_CR36","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","volume":"22","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22:790\u2013800.","journal-title":"Lancet Oncol"},{"key":"2775_CR37","doi-asserted-by":"publisher","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","volume":"7","author":"N Kalakonda","year":"2020","unstructured":"Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020;7:e511\u201322.","journal-title":"Lancet Haematol"},{"key":"2775_CR38","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","volume":"21","author":"G Salles","year":"2020","unstructured":"Salles G, Duell J, Gonz\u00e1lez Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21:978\u201388.","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2775_CR39","doi-asserted-by":"publisher","first-page":"8058","DOI":"10.1182\/blood-2022-167753","volume":"140","author":"M Hamadani","year":"2022","unstructured":"Hamadani M, Liao L, Wilson L, Howarth A, Flores C, Chen L. Real-world outcomes in relapsed\/refractory DLBCL patients who received polatuzumab vedotin PLUS bendamustine and rituximab or tafasitamab plus lenalidomide by line of therapy [abstract]. Blood. 2022;140(suppl 1):8058\u201360.","journal-title":"Blood"},{"issue":"supplement 1","key":"2775_CR40","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1182\/blood-2022-167620","volume":"140","author":"D Qualls","year":"2022","unstructured":"Qualls D, Buege MJ, Dao P, et al. Tafasitamab and lenalidomide in relapsed\/refractory large B cell lymphoma (R\/R LBCL): real world outcomes in a multicenter retrospective study [abstract]. Blood. 2022;140(supplement 1):787\u20139.","journal-title":"Blood"},{"key":"2775_CR41","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1182\/bloodadvances.2020004155","volume":"5","author":"N Liebers","year":"2021","unstructured":"Liebers N, Duell J, Fitzgerald D, et al. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. Blood Adv. 2021;5:2707\u201316.","journal-title":"Blood Adv"},{"key":"2775_CR42","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.jval.2020.06.006","volume":"23","author":"BA Feinberg","year":"2020","unstructured":"Feinberg BA, Gajra A, Zettler ME, Phillips TD, Phillips EG Jr, Kish JK. Use of real-world evidence to support FDA approval of oncology drugs. Value Health. 2020;23:1358\u201365.","journal-title":"Value Health"},{"key":"2775_CR43","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/JBM.S190784","volume":"10","author":"R Mohammed","year":"2019","unstructured":"Mohammed R, Milne A, Kayani K, Ojha U. How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin\u2019s lymphomas. J Blood Med. 2019;10:71\u201384.","journal-title":"J Blood Med"},{"key":"2775_CR44","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1158\/1078-0432.CCR-21-3648","volume":"28","author":"GS Nowakowski","year":"2022","unstructured":"Nowakowski GS, Yoon DH, Peters A, et al. Improved efficacy of tafasitamab plus lenalidomide versus systemic therapies for relapsed\/refractory DLBCL: RE-MIND2, an observational retrospective matched cohort study. Clin Cancer Res. 2022;28:4003\u201317.","journal-title":"Clin Cancer Res"},{"key":"2775_CR45","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.ajodo.2014.08.007","volume":"146","author":"N Pandis","year":"2014","unstructured":"Pandis N. Cohort studies: part 2. Am J Orthod Dentofacial Orthop. 2014;146:686\u20137.","journal-title":"Am J Orthod Dentofacial Orthop"},{"key":"2775_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g1072","volume":"348","author":"P Sedgwick","year":"2014","unstructured":"Sedgwick P. Retrospective cohort studies: advantages and disadvantages. BMJ. 2014;348: g1072.","journal-title":"BMJ"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02775-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02775-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02775-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T18:15:56Z","timestamp":1708452956000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02775-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,2]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["2775"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02775-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,2]]},"assertion":[{"value":"28 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andrew Ip: Honoraria: Pfizer; Speakers Bureau: Seagen; Advisory Board: Secura Bio, AstraZeneca, TG Therapeutics; Equity Interest: COTA. Alex Mutebi, Tongsheng Wang, Monika Jun, Anupama Kalsekar, Fernando Rivas Navarro, Mariana Sacchi, and Brian Elliott: Employees of Genmab and own stock. Anthony Wang and Rajesh Kamalakar: Employees of AbbVie and own stock.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Given that the COTA database houses de-identified, secondary data, this analysis did not require Institutional Review Board approval. All authors had full permission to access and use the COTA EHR database for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}